- Home
- AACG vs LTRN Comparison
AACG vs LTRN Comparison
Compare AACG & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACG
- LTRN
- Stock Information
- Founded
- AACG 1999
- LTRN 2013
- Country
- AACG China
- LTRN United States
- Employees
- AACG N/A
- LTRN N/A
- Industry
- AACG Other Consumer Services
- LTRN Biotechnology: Pharmaceutical Preparations
- Sector
- AACG Real Estate
- LTRN Health Care
- Exchange
- AACG Nasdaq
- LTRN Nasdaq
- Market Cap
- AACG 51.9M
- LTRN 49.9M
- IPO Year
- AACG N/A
- LTRN 2020
- Fundamental
- Price
- AACG $1.31
- LTRN $3.82
- Analyst Decision
- AACG
- LTRN Strong Buy
- Analyst Count
- AACG 0
- LTRN 1
- Target Price
- AACG N/A
- LTRN $25.00
- AVG Volume (30 Days)
- AACG 58.0K
- LTRN 153.5K
- Earning Date
- AACG 11-10-2025
- LTRN 11-14-2025
- Dividend Yield
- AACG N/A
- LTRN N/A
- EPS Growth
- AACG N/A
- LTRN N/A
- EPS
- AACG N/A
- LTRN N/A
- Revenue
- AACG $39,064,701.00
- LTRN N/A
- Revenue This Year
- AACG N/A
- LTRN N/A
- Revenue Next Year
- AACG N/A
- LTRN N/A
- P/E Ratio
- AACG N/A
- LTRN N/A
- Revenue Growth
- AACG 15.19
- LTRN N/A
- 52 Week Low
- AACG $0.70
- LTRN $2.55
- 52 Week High
- AACG $2.58
- LTRN $6.12
- Technical
- Relative Strength Index (RSI)
- AACG 43.09
- LTRN 41.14
- Support Level
- AACG $1.15
- LTRN $3.89
- Resistance Level
- AACG $1.38
- LTRN $4.28
- Average True Range (ATR)
- AACG 0.14
- LTRN 0.32
- MACD
- AACG 0.03
- LTRN -0.04
- Stochastic Oscillator
- AACG 56.82
- LTRN 7.53
About AACG ATA Creativity Global
ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments of the company are (i) Overseas art study services (ii) Other educational services and (iii) Other services. Majority of its revenue comes from Overseas art study services.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.